Skip Nav Destination
Abstract B278: PR610: A novel hypoxia-selective tyrosine kinase inhibitor in phase I clinical trial.
Mol Cancer Ther (2013) 12 (11_Supplement): B278.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
- Irma Telarovic
- Roland H. Wenger
- Martin Pruschy
Journal of Experimental & Clinical Cancer Research (2021) 40 (1)
